Premium
Targeted metabolomics study of early pathological features in hippocampus of triple transgenic Alzheimer’s disease male mice
Author(s) -
Zhao Yuxi,
Chen Haiquan,
Iqbal Javed,
Liu Xukun,
Zhang Huajie,
Xiao Shifeng,
Jin Na,
Yao Fang,
Shen Liming
Publication year - 2021
Publication title -
journal of neuroscience research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.72
H-Index - 160
eISSN - 1097-4547
pISSN - 0360-4012
DOI - 10.1002/jnr.24750
Subject(s) - metabolomics , disease , biology , oxidative stress , genetically modified mouse , alzheimer's disease , transgene , medicine , endocrinology , biochemistry , bioinformatics , gene
Alzheimer's disease (AD) is a serious neurodegenerative disease in people of age 65 or above. The detailed etiology and pathogenesis of AD have not been elucidated yet. In this study, the hippocampi of 2‐ and 6‐month‐old triple transgenic Alzheimer's disease male mice and age–sex‐matched wild‐type (WT) mice were analyzed by using targeted metabolomics approach. Compared with WT mice, 24 and 60 metabolites were found with significant differences in 2‐ and 6‐month‐old AD mice. Among these, 14 metabolites were found common while 10 metabolites showed consistent variable trends in both groups. These differential metabolites are found associated with amino acid, lipid, vitamin, nucleotide‐related base, neurotransmitter and energy metabolisms, and oxidative stress. The results suggest that these differential metabolites might play a critical role in AD pathophysiology, and may serve as potential biomarkers for AD. Moreover, the results highlight the involvement of abnormal purine, pyrimidine, arginine, and proline metabolism, along with glycerophospholipid metabolism in early pathology of AD. For the first time, several differential metabolites are found to be associated with AD in this study. Targeted metabolomics can be used for rapid and accurate quantitative analysis of specific target metabolites associated with AD.